Risk Management

BEOVU

There are two BEOVU forms

Use BEOVU for all adult patients receiving BEOVU. This form was updated on 3/13/20 to add retinal arterial occlusion to the list of complications.

Ask women of child-bearing age to sign Beovu.Possible risk for the fetus about the possible risk to the fetus. The BEOVU prescribing label states that there is a possible risk to the fetus from this and other anti-VEGF drugs. It should only be used in women of childbearing age if the possible benefit for the woman is greater than the potential risk to the fetus.

Review our risk management recommendations on the use of anti-VEGF drugs in adults.

AntiVEFG drugs for adults addresses on- and off-label use, preventing endophthalmitis, informed consent issues, and documentation. It incorporates key guidelines on intravitreal injection published by a panel of experts. It also addresses the FDA warning about Avastin in more detail.

Conduct a time out before each intravitreal injection.

OMIC has received reports of “wrong” events associated with intravitreal injections. These include wrong patient, wrong eye, wrong condition, wrong drug, and wrong dose.

To ensure that the correct drug and dose are injected into the correct eye every time, the ophthalmologist needs to lead a time out.  Time-out before intravitreal injections/ provides the opportunity to confirm that the patient, medical record, and ophthalmologist are in agreement.